- Evaxion Biotech ADS press release (EVAX): Q1 GAAP EPS of $0.03 beats by $0.53.
- Revenue of $0.05M.
- Cash position as of March 31, 2024, was $11.7 million, as compared to $5.6 million as of December 31, 2023.
- The company expects that its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements into Q1 2025.
